(7S,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine | 261944-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (7S,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine
• 英文别名: (7S,8R,9R)-8-hydroxy-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine；(7S,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h]-[1,7]naphthyridine；(7S,8R,9R)-8-hydroxy-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h][1,7]naphthyridin；(7S,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine；(7S,8R,9R)-8-hydroxy-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine；(7S,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol
• CAS: 261944-51-8
• 化学式: C₂₁H₂₅N₃O₃
• 分子量: 367.448
• InChiKey: PWILYDZRJORZDR-RLLQIKCJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (7S,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine 在 sodium acetate 、 乙酸酐 作用下， 生成 (7S,8R,9R)-8-Acetoxy-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine
  参考文献：
  名称：

  Prodrugs of imidazopyridine derivatives

  摘要：

  式（1）化合物，其中取代基具有描述中提到的含义，适用于预防和治疗胃肠疾病。

  公开号：

  US20030125327A1
• 作为产物：
  描述：

  N-(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)-2,2-dimethylpropanamide 在 甲醇 、 sodium tetrahydroborate 、 硫酸 、 叔丁基锂 作用下， 以 乙醚 、 水 、 正戊烷 为溶剂， 反应 67.82h， 生成 (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine 、 (7S,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine
  参考文献：
  名称：

  [EN] TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE
  [FR] TÉTRAHYDROPYRIDOÉTHERS POUR LE TRAITEMENT DE LA MALADIE DE STARGARDT

  摘要：

  一种包含四氢吡啶基乙醚的药物组合物，用于治疗斯塔加特病。

  公开号：

  WO2015052256A1

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• [EN] PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES<br/>[FR] PROMEDICAMENTS DE DERIVES D'IMIDAZOPYRIDINE
  申请人：BYK GULDEN LOMBERG CHEM FAB

  公开号：WO2001072756A1

  公开（公告）日：2001-10-04

  Compounds of formula (1), in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases.

  公式（1）的化合物，其中取代基具有描述中提到的含义，适用于预防和治疗胃肠疾病。
• TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD
  申请人：Schraermeyer Ulrich

  公开号：US20110046377A1

  公开（公告）日：2011-02-24

  A medication comprising tetrahydropyridoethers for use in the treatment of AMD.

  一种含有四氢吡啶乙醚的药物，用于治疗AMD。
• Compositions useful for treating gastrointestinal motility disorders
  申请人：Landau B. Steven

  公开号：US20050059704A1

  公开（公告）日：2005-03-17

  The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an H 2 receptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.

  本发明涉及治疗需要治疗的受试者胃肠道运动紊乱的方法，包括向所述受试者联合施用第一种量的具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液；以及第二种量的至少一种胃酸抑制剂（如质子泵抑制剂、H 2 受体拮抗剂或其药学上可接受的盐、水合物或溶液；或酸泵拮抗剂或其药学上可接受的盐、水合物或溶液），其中第一和第二量共同构成治疗有效量。特别是，该方法用于治疗胃食管反流病，包括夜间胃食管反流病。本发明进一步涉及一种治疗夜间胃食管反流病的方法，该方法包括向有需要的受试者施用治疗有效量的具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液。本发明进一步涉及一种增加需要者食管蠕动的方法。增加食管蠕动的方法可通过给予具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液。联合给药也可用于增加食管运动。
• Combinations and use of selected pharmaceutically active compounds
  申请人：Buhr Wilm

  公开号：US20060154954A1

  公开（公告）日：2006-07-13

  The present invention relates to new combinations and new uses of certain selected tricyclic imidazo [ 1,2 -a]pyridine compounds in the prevention or treatment of medicament caused gastrointestinal diseases.

  本发明涉及某些精选三环咪唑[1,2]的新组合和新用途。 1,2 -a]吡啶化合物在预防或治疗药物引起的胃肠道疾病方面的新组合和新用途。